Capivasertib en association au fulvestrant dans le cancer du sein localement avancé ou métastatique RH+ HER2– avec une altération de PIK3CA, AKT1 ou PTEN, après une première ligne d’hormonothérapie
{"title":"Capivasertib en association au fulvestrant dans le cancer du sein localement avancé ou métastatique RH+ HER2– avec une altération de PIK3CA, AKT1 ou PTEN, après une première ligne d’hormonothérapie","authors":"Victor Heurtier , Alexandre de Nonneville","doi":"10.1016/j.bulcan.2024.08.010","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"111 11","pages":"Pages 997-998"},"PeriodicalIF":1.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455124003072","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
期刊介绍:
Without doubt, the ''Bulletin du Cancer'' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.